Controversy continues to surround Mylan as news broke that the company's top five paid executives made a consolidated $300 million over the course of five years, according to a Wall Street Journal analysis.
Here are six things to know:
1. Among all U.S. drug and biotech firms, Mylan had the second-highest executive compensation.
2. This high ranking is striking due to Mylan's size relative to other leading pharmaceutical players. Mylan ranked number 11 in revenue and number 16 by market capitalization, the WSJ analysis found.
3. As a general rule, companies often pay their executives based on their size relative to competitors in the industry. Larger companies typically offer higher compensation than smaller ones.
4. Of the five executives, Mylan paid three executives nearly $70 million each over the five years. The three executives were ranked among the 20 highest-paid executives in the pharmaceutical industry over the five years.
5. Mylan released a statement saying shareholders have 'consistently approved' its executive compensation program and that changes within the last five years in its management and other matters make it 'impossible' to compare Mylan to its competitors.
6. Mylan has faced heat after news broke about the company increasing EpiPen's price by more than 450 percent since 2004.
More articles on quality & infection control:
Healthmark adds single-use gown to product line: 3 notes
VA stops sending quality information to national database despite 2014 law — 7 key takeaways
University of Utah's value-driven outcomes program increases patient outcomes while decreasing cost: 6 takeaways
